Figure 1.

(a) Current treatment strategies for pancreatic carcinomas; (b) assumed future treatment strategy for pancreatic carcinoma: The most distinctive changes (highlighted in red) are probably (1) an extension of biopsy options and an introduction of routinely molecular tests including chemotherapy sensitivity, (2) an introduction of neoadjuvant therapy even in resectable stage, (3) an improvement of chemotherapy regimens with increased secondary resectability, and (4) the “introduction” of oligometastasis as the fifth subgroup (besides resectable, borderline, locally advanced, and metastatic stages) with enhanced therapy options including surgery in this new group. Dotted frames indicate possible therapy options.